Indeed, NGM282, an analogue of FGF19, has been shown to significantly suppress BA synthesis and reduce ALP, GGT, ALT, AST, IgG, and IgM levels with an acceptable safety profile in PBC patients, including PBC patients unresponsive to UDCA treatment [36, 37]. This evidence concerns the gene FGF19 and primary biliary cholangitis.